Marat Slessarev
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Marat Slessarev has a total of 428 co-authors. Here are the top co-authors by number of shared publications:
Alexandra Mardimae
8 shared publicationsChristopher W. McIntyre
Kidney Clinical Research Unit, Lawson Health Research Institute, London, Ontario, Canada
7 shared publications- Douglas D. Fraser
Physiology and Pharmacology, Western University, London, Canada
6 shared publications - James Duffin
Department of Physiology University of Toronto Toronto Ontario Canada
6 shared publications Joseph A. Fisher
6 shared publications- Claudio M. Martin
Medicine, Western University, London, Canada
5 shared publications
Latest Publications
- 7 September 2026
- Published by Wolters Kluwer Health in Critical Care Medicine
- Vol. 54 (11) , 2924-2934
Ethical and Methodological Features of Cluster Randomized Trials in Critical Care Settings: A Systematic Review
OBJECTIVES: Cluster randomized trials (CRTs) are useful for evaluating system-level interventions in critical care but raise complex ethical and methodological issues that are amplified in this setting. We aimed to describe ethical and methodological features of CRTs in critical care settings. DATA SOURCES: We performed a systematic literature search in MEDLINE and Embase. STUDY SELECTION: We included primary reports of CRTs in critical care settings published from 2004 to 2022 in English. DATA EXTRACTION: Two reviewers independently extracted data from each CRT, resolving any discrepancies by consensus. DATA SYNTHESIS: Among 102 CRTs, 77 CRTs (78%) reported trial registration and 101 CRTs (99%) reported research ethics committee review; five CRTs (5%) were exempted from review. Common designs were parallel-arm (48, 47%), two-period crossover (23, 23%), stepped-wedge (20, 20%), and multi-period crossover (8, 8%). A justification for using cluster randomization was provided in 47 CRTs (46%). Patients and caregivers were identified as research participants in 99 CRTs (97%). Of these, 74 CRTs (75%) reported on consent, which was most commonly waived consent (36, 49%). Healthcare providers were identified as research participants in 48 CRTs (47%). Of these, 11 CRTs (23%) reported on consent. Most (82, 80%) reported a sample size or power calculation, with 67 CRTs (82%) accounting for the intracluster correlation; 77 CRTs (76%) accounted for the intracluster correlation in the primary analysis. Among 85 CRTs with fewer than 40 clusters, 11 CRTs (13%) reported a small sample correction. CONCLUSIONS: Ethical and methodological shortcomings persist in CRTs. Enhanced reporting standards and adherence to established ethical frameworks, including the Ottawa Statement , are needed to ensure both scientific and ethical integrity in this essential design in critical care research.
- 7 September 2026
- Published by Wolters Kluwer Health in Critical Care Medicine
- Vol. 54 (11) , 2924-2934
Ethical and Methodological Features of Cluster Randomized Trials in Critical Care Settings: A Systematic Review
OBJECTIVES: Cluster randomized trials (CRTs) are useful for evaluating system-level interventions in critical care but raise complex ethical and methodological issues that are amplified in this setting. We aimed to describe ethical and methodological features of CRTs in critical care settings. DATA SOURCES: We performed a systematic literature search in MEDLINE and Embase. STUDY SELECTION: We included primary reports of CRTs in critical care settings published from 2004 to 2022 in English. DATA EXTRACTION: Two reviewers independently extracted data from each CRT, resolving any discrepancies by consensus. DATA SYNTHESIS: Among 102 CRTs, 77 CRTs (78%) reported trial registration and 101 CRTs (99%) reported research ethics committee review; five CRTs (5%) were exempted from review. Common designs were parallel-arm (48, 47%), two-period crossover (23, 23%), stepped-wedge (20, 20%), and multi-period crossover (8, 8%). A justification for using cluster randomization was provided in 47 CRTs (46%). Patients and caregivers were identified as research participants in 99 CRTs (97%). Of these, 74 CRTs (75%) reported on consent, which was most commonly waived consent (36, 49%). Healthcare providers were identified as research participants in 48 CRTs (47%). Of these, 11 CRTs (23%) reported on consent. Most (82, 80%) reported a sample size or power calculation, with 67 CRTs (82%) accounting for the intracluster correlation; 77 CRTs (76%) accounted for the intracluster correlation in the primary analysis. Among 85 CRTs with fewer than 40 clusters, 11 CRTs (13%) reported a small sample correction. CONCLUSIONS: Ethical and methodological shortcomings persist in CRTs. Enhanced reporting standards and adherence to established ethical frameworks, including the Ottawa Statement , are needed to ensure both scientific and ethical integrity in this essential design in critical care research.
- Open Access
- 2 July 2026
- Published by Wolters Kluwer Health in Critical Care Explorations
- Vol. 8 (7) , e1437
Apnea Testing for Brain Death/Death by Neurologic Criteria in Adults: A Prospective Multicenter Observational Study Assessing the Relationship Between Methodology, Safety, and Duration
IMPORTANCE: Apnea testing is an integral component of brain death (BD) assessments. The optimal method of Apnea Testing is currently not known. OBJECTIVES: To describe the current use of apnea test methods, and compare the effect of the chosen apnea test method (passive oxygenation, continuous positive airway pressure [CPAP], or exogenous C o 2 ) on safety and duration of apnea test in adult BD/death by neurologic criteria (DNC) organ donors. DESIGN: A prospective multicenter observational study. SETTING: Seventy-four ICUs in Ontario, Canada, who participate in organ donation practices. PATIENTS: All BD/DNC assessments in Ontario, Canada, from July 2023 to August 2024. INTERVENTIONS: None. MAIN OUTCOMES AND MEASURES: Outcomes included the rate of apnea test attempts, completions, and adverse events. We also measured the incidence of each method used and the duration of the apnea test. RESULTS: During the 1-year study period, a total of 368 BD/DNC assessments were performed, of which 361 (98%) attempted an apnea test. Of the 361 apnea tests attempted, 236 (65%) used passive oxygenation (tracheal insufflation), 103 (29%) used CPAP-based methods, and 22 (6%) used exogenous C o 2 . Nine tests were not completed: seven were terminated due to adverse events (all with passive oxygenation; five hypoxemia, two hemodynamic instability) and two due to observed respiratory effort. All adverse events occurred with the passive oxygenation method ( p = 0.20). No statistically significant differences were seen in apnea test duration between methods. The median test durations were 12 minutes (interquartile range [IQR], 10–17 min), 12 minutes (IQR, 8–15 min), and 15 minutes (IQR, 11–25 min) for passive oxygenation, positive pressure, and exogenous C o 2 , respectively. CONCLUSIONS AND RELEVANCE: In this large multicenter study, passive oxygenation was associated with a nonsignificant increase in adverse events compared with CPAP-based and exogenous C o 2 methods. Exogenous C o 2 did not shorten apnea test time. These findings support further investigation of CPAP-based methods as an alternative approach to apnea testing and refinement of C o 2 delivery parameters.
- 2 July 2026
- Published by Wolters Kluwer Health in Critical Care Explorations
- Vol. 8 (7) , e1437
Open AccessApnea Testing for Brain Death/Death by Neurologic Criteria in Adults: A Prospective Multicenter Observational Study Assessing the Relationship Between Methodology, Safety, and Duration
IMPORTANCE: Apnea testing is an integral component of brain death (BD) assessments. The optimal method of Apnea Testing is currently not known. OBJECTIVES: To describe the current use of apnea test methods, and compare the effect of the chosen apnea test method (passive oxygenation, continuous positive airway pressure [CPAP], or exogenous C o 2 ) on safety and duration of apnea test in adult BD/death by neurologic criteria (DNC) organ donors. DESIGN: A prospective multicenter observational study. SETTING: Seventy-four ICUs in Ontario, Canada, who participate in organ donation practices. PATIENTS: All BD/DNC assessments in Ontario, Canada, from July 2023 to August 2024. INTERVENTIONS: None. MAIN OUTCOMES AND MEASURES: Outcomes included the rate of apnea test attempts, completions, and adverse events. We also measured the incidence of each method used and the duration of the apnea test. RESULTS: During the 1-year study period, a total of 368 BD/DNC assessments were performed, of which 361 (98%) attempted an apnea test. Of the 361 apnea tests attempted, 236 (65%) used passive oxygenation (tracheal insufflation), 103 (29%) used CPAP-based methods, and 22 (6%) used exogenous C o 2 . Nine tests were not completed: seven were terminated due to adverse events (all with passive oxygenation; five hypoxemia, two hemodynamic instability) and two due to observed respiratory effort. All adverse events occurred with the passive oxygenation method ( p = 0.20). No statistically significant differences were seen in apnea test duration between methods. The median test durations were 12 minutes (interquartile range [IQR], 10–17 min), 12 minutes (IQR, 8–15 min), and 15 minutes (IQR, 11–25 min) for passive oxygenation, positive pressure, and exogenous C o 2 , respectively. CONCLUSIONS AND RELEVANCE: In this large multicenter study, passive oxygenation was associated with a nonsignificant increase in adverse events compared with CPAP-based and exogenous C o 2 methods. Exogenous C o 2 did not shorten apnea test time. These findings support further investigation of CPAP-based methods as an alternative approach to apnea testing and refinement of C o 2 delivery parameters.
- Open Access
- 28 May 2026
- Published by Wolters Kluwer Health in Critical Care Explorations
- Vol. 8 (6) , e1421
The Tip of the Iceberg: Pathway Biology Must Anchor the Next Generation of Critical Care Trials
Heterogeneity of treatment effect has yielded decades of negative critical care trials. Syndromic diagnoses like sepsis and acute respiratory distress syndrome mask distinct molecular programs that respond differently to the same intervention, and single biomarkers lack the resolution to capture this complexity. Recent evidence now demonstrates that each step of the enrichment pipeline, from real-time bedside endotyping to prospective endotype-matched therapy, is clinically operational. However, current approaches rely on limited biomarker panels that capture only surface-level biology. Pathway biology, examining coordinated dysregulation of molecular networks rather than isolated analytes, offers the deeper resolution needed to match patients to targeted therapies. We propose a translational pipeline integrating multiomics, pathway analysis, machine learning, and point-of-care assays to advance critical care toward pathway-focused predictive enrichment.
- 28 May 2026
- Published by Wolters Kluwer Health in Critical Care Explorations
- Vol. 8 (6) , e1421
Open AccessThe Tip of the Iceberg: Pathway Biology Must Anchor the Next Generation of Critical Care Trials
Heterogeneity of treatment effect has yielded decades of negative critical care trials. Syndromic diagnoses like sepsis and acute respiratory distress syndrome mask distinct molecular programs that respond differently to the same intervention, and single biomarkers lack the resolution to capture this complexity. Recent evidence now demonstrates that each step of the enrichment pipeline, from real-time bedside endotyping to prospective endotype-matched therapy, is clinically operational. However, current approaches rely on limited biomarker panels that capture only surface-level biology. Pathway biology, examining coordinated dysregulation of molecular networks rather than isolated analytes, offers the deeper resolution needed to match patients to targeted therapies. We propose a translational pipeline integrating multiomics, pathway analysis, machine learning, and point-of-care assays to advance critical care toward pathway-focused predictive enrichment.
- Open Access
- 8 May 2026
- Published by Wolters Kluwer Health in Critical Care Explorations
- Vol. 8 (5) , e1416
Supporting Informed Surrogate Decision-Making in Deceased Donor Intervention Research: Co-Creating Educational Materials With Families
Deceased donor intervention research aims to improve organ donation and transplantation outcomes, but its feasibility often depends on obtaining valid informed consent from surrogate decision makers during a difficult time for families in the ICU. Consent discussions may be complicated by grief, decisional burden, and the complexity of donor interventions, creating risks to comprehension, trust, and voluntariness. In this letter, we describe a collaborative model for co-creating consent and educational materials with deceased donors’ family members developed for a donor intervention trial in Canada. We outline our co-creation process and present five practical lessons learned, emphasizing trust, visual communication, standardization, the supportive role of educational tools, and iterative refinement. Our experience demonstrates that materials developed in partnership with donor families can enhance clarity, relevance, and sensitivity while supporting research coordinators. Our approach offers a scalable framework for improving informed consent processes and facilitating ethically robust donor intervention research.
- 8 May 2026
- Published by Wolters Kluwer Health in Critical Care Explorations
- Vol. 8 (5) , e1416
Open AccessSupporting Informed Surrogate Decision-Making in Deceased Donor Intervention Research: Co-Creating Educational Materials With Families
Deceased donor intervention research aims to improve organ donation and transplantation outcomes, but its feasibility often depends on obtaining valid informed consent from surrogate decision makers during a difficult time for families in the ICU. Consent discussions may be complicated by grief, decisional burden, and the complexity of donor interventions, creating risks to comprehension, trust, and voluntariness. In this letter, we describe a collaborative model for co-creating consent and educational materials with deceased donors’ family members developed for a donor intervention trial in Canada. We outline our co-creation process and present five practical lessons learned, emphasizing trust, visual communication, standardization, the supportive role of educational tools, and iterative refinement. Our experience demonstrates that materials developed in partnership with donor families can enhance clarity, relevance, and sensitivity while supporting research coordinators. Our approach offers a scalable framework for improving informed consent processes and facilitating ethically robust donor intervention research.
- 23 January 2026
- Published by Oxford University Press (OUP) in American Journal of Respiratory and Critical Care Medicine
- Vol. 212 (3) , 404-407
Mobilizing smarter, not harder: optimizing mobilization in critical illness
- 23 January 2026
- Published by Oxford University Press (OUP) in American Journal of Respiratory and Critical Care Medicine
- Vol. 212 (3) , 404-407
Mobilizing smarter, not harder: optimizing mobilization in critical illness
- Open Access
- 19 November 2025
- Published by Elsevier in American Journal of Transplantation
- Vol. 26 (3) , 449-454
Organ procurement organizations should develop policy regarding surrogate consent for normothermic regional perfusion
- 19 November 2025
- Published by Elsevier in American Journal of Transplantation
- Vol. 26 (3) , 449-454
Open AccessOrgan procurement organizations should develop policy regarding surrogate consent for normothermic regional perfusion
- Open Access
- 10 July 2025
- Published by Wolters Kluwer Health in Critical Care Explorations
- Vol. 7 (7) , e1280
Effect of Inhaled Volatile and IV Anesthetics on Biological Markers of Inflammation in Adult ICU and Thoracic Surgical Patients: A Systematic Review and Meta-Analysis
OBJECTIVES: Inhaled anesthetics may reduce alveolar and systemic inflammation in surgical and critically ill patients. This study aimed to perform a systematic review and meta-analysis comparing the effect of inhaled volatile and IV anesthetics on alveolar and plasma cytokines in patients with surgical or medical acute lung injury. DATA SOURCES: Medline, Embase, and Cochrane CENTRAL databases from 2000 to July 2021. STUDY SELECTION: Randomized control trials, prospective, and retrospective observational studies comparing inhaled volatile to IV anesthetics in ventilated adult patients with acute lung injury from lung resection or critical illness. DATA EXTRACTION: A systematic review and meta-analysis was performed. Primary outcome was alveolar inflammatory cytokines levels that were meta-analyzed using a random effects model. Secondary outcomes were plasma inflammatory cytokine levels, mortality, pulmonary complications, and duration of hospital and ICU stay. The quality of studies was assessed using the Cochrane Risk of Bias tool for randomized control trials and the Cochrane Risk Of Bias In Non-randomized Studies of Interventions tool for retrospective cohort studies. DATA SYNTHESIS: From 2522 screened studies, 28 (27 thoracic surgery and 1 ICU, n = 4175) were included. Meta-analysis of patients undergoing lung resection demonstrated lower levels of alveolar tumor necrosis factor-alpha (TNF-α) (standard mean difference 1.04; 95% CI, 0.32–1.77; p < 0.01; I 2 82%) and interleukin (IL)-6 (0.64; 95% CI, 0.52–0.75; I 2 0%; p < 0.01) at 1–2 hours in the inhaled anesthesia group, with no difference in other cytokines at various time points. The single ICU study demonstrated lower plasma TNF-α and IL-6 and alveolar TNF-α, IL-6, and IL-8 at 48 hours in patients sedated with sevoflurane compared with midazolam. Clinical outcomes were infrequently reported. CONCLUSIONS: Limited evidence suggests that inhaled anesthesia may reduce proinflammatory cytokines TNF-α and IL-6 during lung resection and critical illness. Further studies are needed to clarify its effects on biological markers and clinical outcomes.
- 10 July 2025
- Published by Wolters Kluwer Health in Critical Care Explorations
- Vol. 7 (7) , e1280
Open AccessEffect of Inhaled Volatile and IV Anesthetics on Biological Markers of Inflammation in Adult ICU and Thoracic Surgical Patients: A Systematic Review and Meta-Analysis
OBJECTIVES: Inhaled anesthetics may reduce alveolar and systemic inflammation in surgical and critically ill patients. This study aimed to perform a systematic review and meta-analysis comparing the effect of inhaled volatile and IV anesthetics on alveolar and plasma cytokines in patients with surgical or medical acute lung injury. DATA SOURCES: Medline, Embase, and Cochrane CENTRAL databases from 2000 to July 2021. STUDY SELECTION: Randomized control trials, prospective, and retrospective observational studies comparing inhaled volatile to IV anesthetics in ventilated adult patients with acute lung injury from lung resection or critical illness. DATA EXTRACTION: A systematic review and meta-analysis was performed. Primary outcome was alveolar inflammatory cytokines levels that were meta-analyzed using a random effects model. Secondary outcomes were plasma inflammatory cytokine levels, mortality, pulmonary complications, and duration of hospital and ICU stay. The quality of studies was assessed using the Cochrane Risk of Bias tool for randomized control trials and the Cochrane Risk Of Bias In Non-randomized Studies of Interventions tool for retrospective cohort studies. DATA SYNTHESIS: From 2522 screened studies, 28 (27 thoracic surgery and 1 ICU, n = 4175) were included. Meta-analysis of patients undergoing lung resection demonstrated lower levels of alveolar tumor necrosis factor-alpha (TNF-α) (standard mean difference 1.04; 95% CI, 0.32–1.77; p < 0.01; I 2 82%) and interleukin (IL)-6 (0.64; 95% CI, 0.52–0.75; I 2 0%; p < 0.01) at 1–2 hours in the inhaled anesthesia group, with no difference in other cytokines at various time points. The single ICU study demonstrated lower plasma TNF-α and IL-6 and alveolar TNF-α, IL-6, and IL-8 at 48 hours in patients sedated with sevoflurane compared with midazolam. Clinical outcomes were infrequently reported. CONCLUSIONS: Limited evidence suggests that inhaled anesthesia may reduce proinflammatory cytokines TNF-α and IL-6 during lung resection and critical illness. Further studies are needed to clarify its effects on biological markers and clinical outcomes.
- Open Access
- 9 June 2025
- Published by Elsevier in American Journal of Transplantation
- Vol. 25 (10) , 2142-2150
The relationship between cessation of brain and systemic circulation after withdrawal of life-sustaining measures
- 9 June 2025
- Published by Elsevier in American Journal of Transplantation
- Vol. 25 (10) , 2142-2150
Open AccessThe relationship between cessation of brain and systemic circulation after withdrawal of life-sustaining measures
- 14 May 2025
- Published by Elsevier in Contemporary Clinical Trials
- Vol. 154, 107938
Coenrollment in a critical care trial: Characteristics and consequences
- 14 May 2025
- Published by Elsevier in Contemporary Clinical Trials
- Vol. 154, 107938
Coenrollment in a critical care trial: Characteristics and consequences